<?xml version="1.0" encoding="iso-8859-1"?> 
<rss version="2.0" xmlns:creativeCommons="http://backend.userland.com/creativeCommonsRssModule" 
xmlns:dc="http://purl.org/dc/elements/1.1/"
xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" 
xmlns:atom="http://www.w3.org/2005/Atom"
>
<channel>
<title>Journal of Cancer</title> 
<link>http://www.jcancer.org</link> 
<description>Journal of Cancer RSS feed -- Volume 4</description> 
<language>en-us</language> 
<pubDate>Thu, 3 Jan 2013 04:00:00 GMT</pubDate>
<lastBuildDate>Thu, 3 Jan 2013 04:00:00 GMT</lastBuildDate> 

<item>
<link>http://www.jcancer.org/v04p0117.htm</link> 
<title>Treating Breast Cancer in the 21st Century: Emerging Biological Therapies</title> 
<description><![CDATA[ <p>For many years, the medical treatment of breast cancer was reliant solely on cytotoxic chemotherapy. However, over the past twenty years, treatment has evolved to a more target-directed approach. We now employ tailored therapy based on the presence or absence of receptors for estrogen, progesterone, and human epidermal growth factor 2 (HER2). We expect this trend to continue, as agents that use novel approaches to target HER2, as well as targeting different portions of the HER signaling pathway, are in various stages of development. Notably, pertuzumab, a humanized monoclonal antibody that binds to a different domain of the extracellular portion of the HER2 receptor than trastuzumab, was recently approved for use, as was lapatinib, a small-molecule tyrosine kinase inhibitor. Patients with triple negative breast cancer, particularly those with the BRCA mutation, have more limited treatment options and carry a worse prognosis than those who are hormone receptor positive. However, recent data has shown that PARP inhibitors may have significant anti-tumor effect in those with this subtype of breast cancer. Novel agents that inhibit mTOR, PI3K, the insulin-like growth factor, heat shock protein 90, and histone deacetylase have shown promise in phase I-III trials and offer exciting new possibilities for the treatment of this often fatal disease. As we are presented with an ever increasing number of treatment options, the timing and combinations of therapeutic agents used becomes ever more complex in the age of personalized care, but we are hopeful that ultimately this will lead to improved patient outcomes.</p> ]]></description>  
<dc:creator>Gabriel Tinoco, Sean Warsch, Stefan Gl&#252;ck, Kiran Avancha, Alberto J. Montero</dc:creator>
<dc:source>Journal of Cancer</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>4</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>117</prism:startingPage> 
<prism:endingPage>132</prism:endingPage> 
<pubDate>2013-1-1</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.jcancer.org/v04p0104.htm</link> 
<title>In Vitro Assessment of the Inflammatory Breast Cancer Cell Line SUM 149: Discovery of 2 Single Nucleotide Polymorphisms in the RNase L Gene</title> 
<description><![CDATA[ <p><b>Background: </b>Inflammatory breast cancer (IBC) is a rare, highly aggressive form of breast cancer. The mechanism of IBC carcinogenesis remains unknown. We sought to evaluate potential genetic risk factors for IBC and whether or not the IBC cell lines SUM149 and SUM190 demonstrated evidence of viral infection.</p><p><b>Methods: </b>We performed single nucleotide polymorphism (SNP) genotyping for 2 variants of the ribonuclease (RNase) L gene that have been correlated with the risk of prostate cancer due to a possible viral etiology. We evaluated dose-response to treatment with interferon-alpha (IFN-&#945;); and assayed for evidence of the putative human mammary tumor virus (HMTV, which has been implicated in IBC) in SUM149 cells. A bioinformatic analysis was performed to evaluate expression of RNase L in IBC and non-IBC.</p><p><b>Results:</b> 2 of 2 IBC cell lines were homozygous for RNase L common missense variants 462 and 541; whereas 2 of 10 non-IBC cell lines were homozygous positive for the 462 variant (<i>p</i>= 0.09) and 0 of 10 non-IBC cell lines were homozygous positive for the 541 variant (<i>p</i> = 0.015). Our real-time polymerase chain reaction (RT-PCR) and Southern blot analysis for sequences of HMTV revealed no evidence of the putative viral genome.</p><p><b>Conclusion:</b> We discovered 2 SNPs in the RNase L gene that were homozygously present in IBC cell lines. The 462 variant was absent in non-IBC lines. Our discovery of these SNPs present in IBC cell lines suggests a possible biomarker for risk of IBC. We found no evidence of HMTV in SUM149 cells. A query of a panel of human IBC and non-IBC samples showed no difference in RNase L expression. Further studies of the RNase L 462 and 541 variants in IBC tissues are warranted to validate our <i>in vitro</i> findings.</p> ]]></description>  
<dc:creator>Brandon T. Nokes, Heather E. Cunliffe, Bonnie LaFleur, David W. Mount, Robert B. Livingston, Bernard W. Futscher, Julie E. Lang</dc:creator>
<dc:source>Journal of Cancer</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>4</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>104</prism:startingPage> 
<prism:endingPage>116</prism:endingPage> 
<pubDate>2012-12-16</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.jcancer.org/v04p0096.htm</link> 
<title>Crosstalk between Wnt Signaling and RNA Processing in Colorectal Cancer</title> 
<description><![CDATA[ <p>RNA processing involves a variety of processes affecting gene expression, including the removal of introns through RNA splicing, as well as 3' end processing (cleavage and polyadenylation). Alternative RNA processing is fundamentally important for gene regulation, and aberrant processing is associated with the initiation and progression of cancer. Deregulated Wnt signaling, which is the initiating event in the development of most cases of human colorectal cancer (CRC), has been linked to modified RNA processing, which may contribute to Wnt-mediated colonic carcinogenesis. Crosstalk between Wnt signaling and alternative RNA splicing with relevance to CRC includes effects on the expression of Rac1b, an alternatively spliced gene associated with tumorigenesis, which exhibits alternative RNA splicing that is influenced by Wnt activity. In addition, Tcf4, a crucial component of Wnt signaling, also exhibits alternative splicing, which is likely involved in colonic tumorigenesis. Modulation of 3' end formation, including of the Wnt target gene <i>COX-2</i>, also can influence the neoplastic process, with implications for CRC. While many human genes are dependent on introns and splicing for normal levels of gene expression, naturally intronless genes exist with a unique metabolism that allows for intron-independent gene expression. Effects of Wnt activity on the RNA metabolism of the intronless Wnt-target gene <i>c-jun</i> is a likely contributor to cancer development. Further, butyrate, a breakdown product of dietary fiber and a histone deacetylase inhibitor, upregulates Wnt activity in CRC cells, and also modulates RNA processing; therefore, the interplay between Wnt activity, the modulation of this activity by butyrate, and differential RNA metabolism in colonic cells can significantly influence tumorigenesis. Determining the role played by altered RNA processing in Wnt-mediated neoplasia may lead to novel interventions aimed at restoring normal RNA metabolism for therapeutic benefit. Therefore, this minireview presents a brief overview of several aspects of RNA processing of relevance to cancer, which potentially influence, or are influenced by, Wnt signaling activity.</p> ]]></description>  
<dc:creator>Michael Bordonaro</dc:creator>
<dc:source>Journal of Cancer</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>4</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>96</prism:startingPage> 
<prism:endingPage>103</prism:endingPage> 
<pubDate>2012-12-15</pubDate>
<category>Mini-review</category>
</item>

<item>
<link>http://www.jcancer.org/v04p0084.htm</link> 
<title>Tumor-Infiltrating Immune Cells Promoting Tumor Invasion and Metastasis: Existing Theories</title> 
<description><![CDATA[ <p>It is a commonly held belief that infiltration of immune cells into tumor tissues and direct physical contact between tumor cells and infiltrated immune cells is associated with physical destructions of the tumor cells, reduction of the tumor burden, and improved clinical prognosis. An increasing number of studies, however, have suggested that aberrant infiltration of immune cells into tumor or normal tissues may promote tumor progression, invasion, and metastasis. Neither the primary reason for these contradictory observations, nor the mechanism for the reported diverse impact of tumor-infiltrating immune cells has been elucidated, making it difficult to judge the clinical implications of infiltration of immune cells within tumor tissues. This mini-review presents several existing hypotheses and models that favor the promoting impact of tumor-infiltrating immune cells on tumor invasion and metastasis, and also analyzes their strength and weakness.</p> ]]></description>  
<dc:creator>Yan-gao Man, Alexander Stojadinovic, Jeffrey Mason, Itzhak Avital, Anton Bilchik, Bjoern Bruecher, Mladjan Protic, Aviram Nissan, Mina Izadjoo, Xichen Zhang, Anahid Jewett</dc:creator>
<dc:source>Journal of Cancer</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>4</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>84</prism:startingPage> 
<prism:endingPage>95</prism:endingPage> 
<category>Review</category>
</item>

<item>
<link>http://www.jcancer.org/v04p0066.htm</link> 
<title>The Tumor Microenvironment Contribution to Development, Growth, Invasion and Metastasis of Head and Neck Squamous Cell Carcinomas</title> 
<description><![CDATA[ <p>Head and neck squamous cell carcinoma (HNSCC) is a complex tissue that contains tumor cells and the surrounding stroma, which is populated by different types of mesenchymal cells and the extracellular matrix (ECM). Collectively, they are referred to as the tumor microenvironment (TME). Recent studies have shown that TME has a more profound influence on the growth and metastasis of HNSCC than was previously appreciated. Because carcinoma-associated fibroblasts (CAFs) are frequently observed in the stroma of the tumor, this review focuses on the potential role of tumor-CAFs interactions in progression of HNSCC. Tumor-CAFs crosstalk enhances the production of growth factors, cytokines, chemokines, matrix metalloproteinases (MMPs), and inflammatory mediators, which eventually facilitates tumor growth. In fact, factors and cells that do not support tumor growth are usually down regulated or mitigated in TME. Therefore TME may determine the fate of the tumors at the site of invasion and metastasis. For tumor cells that survive at these sites, stromal activation may serve to establish a supportive tumor stroma, fostering the outgrowth of the metastatic cells. The concept of tumor-stromal interactions and microenvironmental niche has profound consequences in tumor growth and metastasis and therefore, it's understanding will open up new strategies for the diagnosis, prognosis and therapy of HNSCC.</p> ]]></description>  
<dc:creator>Sittichai Koontongkaew</dc:creator>
<dc:source>Journal of Cancer</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>4</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>66</prism:startingPage> 
<prism:endingPage>83</prism:endingPage> 
<pubDate>2013-1-1</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.jcancer.org/v04p0057.htm</link> 
<title>IL-22: An Evolutionary Missing-Link Authenticating the Role of the Immune System in Tissue Regeneration</title> 
<description><![CDATA[ <p>Tissue regeneration is a critical component of organ maintenance. The ability of lymphocytes to kill pathogen-infected cells has been well-studied. However, the necessity for lymphocytes to participate in reconstruction of destroyed tissues has not been explored until recently. Interleukin (IL)-22, a newly defined cytokine exclusively produced by subsets of lymphocytes, provides the strongest proof yet for the tissue regenerative potentials of the immune system. IL-22 plays an obligatory role in epithelial homeostasis in the gut, liver and lung. The receptor for IL-22 (IL-22R1 and IL-10R2) is predominantly expressed by epithelial cells. While the pro-inflammatory effect is questioned, the pro-constructive potential of IL-22 is well established. It is evident from the response to IL-22, that epithelial cells not only produce anti-microbial peptides but also actively proliferate. Aryl hydrocarbon receptor (AhR) and retinoic acid-related orphan receptor (ROR&#947;t) transcription factor are required for IL-22 generation from Lymphoid Tissue inducer cells LTi, Th22 and NK-like cells. However, IL-22 production from conventional NK cells is independent of AhR and ROR&#947;t. In this review, we present a case for a paradigm shift in how we define the function of the immune system. This would include tissue regeneration as a legitimate immune function.</p> ]]></description>  
<dc:creator>Pawan Kumar, Kamalakannan Rajasekaran, Jeanne M Palmer, Monica S Thakar, Subramaniam Malarkannan</dc:creator>
<dc:source>Journal of Cancer</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>4</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>57</prism:startingPage> 
<prism:endingPage>65</prism:endingPage> 
<pubDate>2013-1-1</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.jcancer.org/v04p0045.htm</link> 
<title>Cystatins in Immune System</title> 
<description><![CDATA[ <p>Cystatins comprise a large superfamily of related proteins with diverse biological activities. They were initially characterised as inhibitors of lysosomal cysteine proteases, however, in recent years some alternative functions for cystatins have been proposed. Cystatins possessing inhibitory function are members of three families, family I (stefins), family II (cystatins) and family III (kininogens). Stefin A is often linked to neoplastic changes in epithelium while another family I cystatin, stefin B is supposed to have a specific role in neuredegenerative diseases. Cystatin C, a typical type II cystatin, is expressed in a variety of human tissues and cells. On the other hand, expression of other type II cystatins is more specific. Cystatin F is an endo/lysosome targeted protease inhibitor, selectively expressed in immune cells, suggesting its role in processes related to immune response. Our recent work points on its role in regulation of dendritic cell maturation and in natural killer cells functional inactivation that may enhance tumor survival. Cystatin E/M expression is mainly restricted to the epithelia of the skin which emphasizes its prominent role in cutaneous biology. Here, we review the current knowledge on type I (stefins A and B) and type II cystatins (cystatins C, F and E/M) in pathologies, with particular emphasis on their suppressive vs. promotional function in the tumorigenesis and metastasis. We proposed that an imbalance between cathepsins and cystatins may attenuate immune cell functions and facilitate tumor cell invasion.</p> ]]></description>  
<dc:creator>&#352;pela Magister, Janko Kos</dc:creator>
<dc:source>Journal of Cancer</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>4</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>45</prism:startingPage> 
<prism:endingPage>56</prism:endingPage> 
<category>Review</category>
</item>

<item>
<link>http://www.jcancer.org/v04p0036.htm</link> 
<title>Dendritic Cells in the Cancer Microenvironment</title> 
<description><![CDATA[ <p>The complexity of the tumor immunoenvironment is underscored by the emergence and discovery of different subsets of immune effectors and regulatory cells. Tumor-induced polarization of immune cell differentiation and function makes this unique environment even more intricate and variable. Dendritic cells (DCs) represent a special group of cells that display different phenotype and activity at the tumor site and exhibit differential pro-tumorigenic and anti-tumorigenic functions. DCs play a key role in inducing and maintaining the antitumor immunity, but in the tumor environment their antigen-presenting function may be lost or inefficient. DCs might be also polarized into immunosuppressive/tolerogenic regulatory DCs, which limit activity of effector T cells and support tumor growth and progression. Although various factors and signaling pathways have been described to be responsible for abnormal functioning of DCs in cancer, there are still no feasible therapeutic modalities available for preventing or reversing DC malfunction in tumor-bearing hosts. Thus, better understanding of DC immunobiology in cancer is pivotal for designing novel or improved therapeutic approaches that will allow proper functioning of DCs in patients with cancer.</p> ]]></description>  
<dc:creator>Yang Ma, Galina V. Shurin, Zhu Peiyuan, Michael R. Shurin</dc:creator>
<dc:source>Journal of Cancer</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>4</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>36</prism:startingPage> 
<prism:endingPage>44</prism:endingPage> 
<pubDate>2012-12-15</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.jcancer.org/v04p0025.htm</link> 
<title>Clinical Relevance of Natural Killer Cells Following Hematopoietic Stem Cell Transplantation</title> 
<description><![CDATA[ <p>Natural killer (NK) cells are one of the first cells to recover following allogeneic hematopoietic stem cell transplantation (HSCT), and are believed to play an important role in facilitating engraftment or preventing post-transplant infection and tumor recurrence. Recent studies have provided novel insights into the mechanisms by which NK cells mediate these highly clinically relevant immunological functions. In particular, the ability of NK cells to reduce the risk of graft versus host disease (GVHD) and increase the graft versus leukemia effect (GVL) in the setting of human leukocyte antigen (HLA)-haploidentical HSCT highlights their clinical potentials. NK cells also mediate anti-viral protection, in particular against cytomegalovirus (CMV), an infection that causes significant morbidity and mortality following transplant. Another crucial function of NK cells is providing protection against bacterial infections at the mucosal barriers. NK cells achieve this by promoting anti-microbial defenses and regeneration of epithelial cells. These recent exciting findings provide a strong basis for the formulation of novel NK cell-based immunotherapies. In this review, we summarize the recent advances related to the mechanisms, functions, and future clinical prospects of NK cells that can impact post-transplant outcomes.</p> ]]></description>  
<dc:creator>Jeanne M Palmer, Kamalakannan Rajasekaran, Monica S Thakar, Subramaniam Malarkannan</dc:creator>
<dc:source>Journal of Cancer</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>4</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>25</prism:startingPage> 
<prism:endingPage>35</prism:endingPage> 
<pubDate>2012-12-5</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.jcancer.org/v04p0012.htm</link> 
<title>Dual Functions of Natural Killer Cells in Selection and Differentiation of Stem Cells; Role in Regulation of Inflammation and Regeneration of Tissues</title> 
<description><![CDATA[ <p>Accumulated evidence from our laboratory indicates that conditioned or anergized NK cells have the ability to induce resistance of healthy stem cells and transformed cancer stem cells through both secreted factors and direct cell-cell contact by inducing differentiation. Cytotoxic function of NK cells is suppressed in the tumor microenvironment by a number of distinct effectors and their secreted factors. Furthermore, decreased peripheral blood NK cell function has been documented in many cancer patients. We have previously shown that NK cells mediate significant cytotoxicity against primary oral squamous carcinoma stem cells (OSCSCs) as compared to their more differentiated oral squamous carcinoma cells (OSCCs). In addition, human embryonic stem cells (hESCs), human mesenchymal stem cells (hMSCs), human dental pulp stem cells (hDPSCs) and induced human pluripotent stem cells (hiPSCs) were all significantly more susceptible to NK cell mediated cytotoxicity than their differentiated counterparts or parental cells from which they were derived. We have also reported that inhibition of differentiation or reversion of cells to a less-differentiated phenotype by blocking NF&#954;B or gene deletion of COX2 significantly augmented NK cell function. Furthermore, the induction of resistance of the stem cells to NK cell mediated cytotoxicity and their subsequent differentiation is amplified when either the stem cells or the NK cells were cultured in the presence of monocytes. Therefore, we propose that the two stages of NK cell maturation namely CD16+CD56dimCD69- NK cells are important for the lysis of stem cells or poorly differentiated cells whereas the CD16dim/-CD56dim/+CD69+NK cells are important for differentiation and eventual regeneration of the tissues and the resolution of inflammation, thus functionally serving as regulatory NK cells (NK<sub>reg</sub>). CD16 receptor on the NK cells were found to be the receptor with significant potential to induce NK cell anergy, however, our recent data indicated that NKp46 but not NKp30 or NKp44 were also able to induce significant anergy in NK cells, although the levels were less when compared to CD16 receptor triggering. The concept of split anergy in NK cells and generation of NK<sub>reg</sub> and its contribution to cell differentiation, tissue repair and regeneration and in tumor resistance will be discussed in this review.</p> ]]></description>  
<dc:creator>Anahid Jewett, Yan-Gao Man, Han-Ching Tseng</dc:creator>
<dc:source>Journal of Cancer</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>4</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>12</prism:startingPage> 
<prism:endingPage>24</prism:endingPage> 
<pubDate>2012-12-1</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.jcancer.org/v04p0003.htm</link> 
<title>Myeloid-Derived Suppressor Cells Interact with Tumors in Terms of Myelopoiesis, Tumorigenesis and Immunosuppression: Thick as Thieves</title> 
<description><![CDATA[ <p>Tumor progression is often associated with chronic inflammation in the tumor microenvironment, which is mediated by numerous cytokines, chemokines and growth factors produced by cancer and stroma cells. All these mediators support tumor development and immunosuppression in autocrine and/or paracrine ways. Neutralization of chronic inflammatory conditions can lead to the restoration of anti-tumor immune responses. Among stroma cells infiltrating tumors, myeloid-derived suppressor cells (MDSCs) represent one of the most important players mediating immunosuppression. These cells may not only inhibit an anti-tumor immunity but also directly stimulate tumorigenesis as well as tumor growth and expansion. Therefore, understanding the mechanisms of generation, migration to the tumor site and activation of MDSC is necessary for the development of new strategies of tumor immunotherapy.</p> ]]></description>  
<dc:creator>Alexandra Sevko, Viktor Umansky</dc:creator>
<dc:source>Journal of Cancer</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>4</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>3</prism:startingPage> 
<prism:endingPage>11</prism:endingPage> 
<pubDate>2012-11-20</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.jcancer.org/v04p0001.htm</link> 
<title>Special Issue on Immune Responses in Tumors and Non-Transformed Inflammatory Microenvironments</title> 
<description><![CDATA[  ]]></description>  
<dc:creator>Anahid Jewett</dc:creator>
<dc:source>Journal of Cancer</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>4</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>1</prism:startingPage> 
<prism:endingPage>2</prism:endingPage> 
<pubDate>2012-11-20</pubDate>
<category>Editorial</category>
</item>

<atom:link href="http://www.jcancer.org/rss/current.xml" rel="self" type="application/rss+xml" />
  </channel>
</rss>
